Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction

Abstract

The invention belongs to the field of a traditional Chinese medicine, and relates to application of a pharmaceutical composition containing folium artemisiae argyi in preparing a medicine for treating myocardial infarction. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 10-15 parts of rhizoma gastrodiae, 10-15 parts of folium artemisiae argyi, 8-13 parts of radix ilicis pubescentis, 5-10 parts of ligusticum wallichii, 5-10 parts of radix paeoniae rubra, 3-8 parts of apocynum venetum, 3-8 parts of radix paeoniae alba, 1-6 parts of red rhodobryum, 1-6 parts of arillus longan, 1-8 parts of Chinese yam and 1-10 parts of liquorice root. The pharmaceutical composition disclosed by the invention has functions of promoting blood circulation to remove meridian obstruction, tranquilizing by nourishing heart, calming liver and relieving pain, nourishing spleen and tonifying qi; and in addition, the pharmaceutical composition also has advantages of being simple in preparation process, good in curative effect, low in side effects, convenient to take, easy in popularization and application, and the like.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to the use of a medicinal composition containing leaves of mugwort for preparing a medicine for treating myocardial infarction. Background technique [0002] Myocardial infarction refers to the occlusion of a coronary artery, causing necrosis of the corresponding part of the myocardium due to severe ischemia. Clinically, there are severe and persistent retrosternal pain, fever, leukocytosis, accelerated erythrocyte sedimentation rate, increased serum myocardial enzyme activity and progressive ECG changes, and arrhythmia, shock or heart failure may occur. Most patients with this disease are accompanied by or have hypertension before the onset, and nearly half of the patients have a history of angina pectoris in the past. People who smoke, are obese, have diabetes, and are physically inactive are more susceptible to the disease. [0003] The basic ca...

AI Technical Summary

Problems solved by technology

[0004] Chinese patent application 201410113088.8 discloses a pharmaceutical composition for the treatment of myocardial infarction. The raw materials for its preparation include: gallnut, honeysuckle, eucommia, thistle, chuanxiong, rehmannia glutinosa, cicada slough, poria cocos, white peony root, codonopsis and licorice. It has a good therapeutic effect in the treatment of myocardial infarction and has significant clinical promotion value, but the effect in nourishing qi and nourishing yin, promoting blood circulation and removing blood stasis is not very significant

[0005] Chinese patent application 201410402574.1 discloses a traditional Chinese medicine for the treatment of myocardial infarction. Its main index raw materials include: Codonopsis, Polygonatum, Ganoderma lucidum, Wintergreen, Astragalus, Guizhi, and Radix Paeoniae Rubra, etc. High, not conducive to industrial production

Images